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INCREASED CD4CD25HIGH REGULATORY T-CELL ARE ASSOCI-
ATED WITH DISEASE RELAPSE AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION (SCT) FOR CHRONIC MYELOID LEUKAEMIA (CML)
Nadal, E.1,2, Kaeda, J.1, Apperley, J.F.1, Lechler, R.2, Dazzi, F.1,2
1Haematology Department Hammersmith Hospital, Imperial College,
London, United Kingdom; 2Immunology Department Hammersmith
Hosppital, Imperial College, London, United Kingdom.
The success of SCT after CML largely relies on the graft versus
leukaemia (GvL) effect exert by donor T-cells. CD4CD25 regu-
latory T-cell (Tregs) play a crucial role in the maintenance of periph-
eral tolerance and have been tested in animal models to successfully
prevent GVHD. The role of Tregs in clinical transplantation remains
unclear, insofar as the few studies published to date have reported
controversial results regarding GvHD. Although there is emerging
evidence that Tregs are associated with a poor outcome in cancer
patients, none of these studies has investigated the role of Tregs in
leukaemia relapse post-SCT.
To address this question we quantiﬁed CD4CD25high regula-
tory T-cells in post-SCT patients and correlated their levels with
clinical outcome.
We performed a cross-sectional study at a single institution. We
enumerated and characterised peripheral blood CD4CD25high
Tregs in 76 patients after allogeneic SCT for CML by FACS
analysis. As control we analysed 21 samples from healthy volun-
teers and 20 samples from newly diagnosed CML patients. BCR-
ABL/ABL ratio was determined in every sample by real-time PCR.
Patients were considered in remission if the ratio was less than
0.02% and in relapse if higher. All quoted p-values are two-sided
with P0.05 considered statistically signiﬁcant.
Patients after SCT had higher levels of Treg than normal donors
(median 1.5% vs 0.87, p0.01) and untreated CML (median 1.5% vs
0.27, p0.0001). In the multiple regression analysis only the time post
SCT (before or after 18 months) and disease status (molecular remis-
sion versus relapse) were predictive for increased Tregs (Coef -2.994,
p0.004 and Coef -2.395, p0.020 respectively). No association with
Treg levels and GvHD was found. The logistic regression analysis
performed in 43 patients that had not received DLI post SCT con-
ﬁrmed that increased Tregs, both as percentage or absolute numbers,
were the only predictive variable for relapse (exp 1.44, p0.011).
A substantial expansion of Tregs occurs early after allogeneic
SCT and the presence of high numbers of Tregs 18 months after
transplant is predictive of leukaemic relapse. Although the incre-
ment might initially have an advantageous effect on graft rejection,
our data suggest that Tregs exert an inhibitory effect on GvL.
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PRESERVED ANTI-VIRAL RESPONSES AND IMPROVED SURVIVAL IN
STEROID REFRACTORY GVHD USING A COMBINATION OF DACLIZUMAB
AND INFLIXIMAB
Rao, K.1, Rao, A.1, Karlsson, H.2, Veys, P.1, Amrolia, P.1,2 1Great
Ormond Street Hospital, London, United Kingdom; 2Institute of Child
Health, London, United Kingdom.
Steroid refractory acute graft versus host disease (SRGvHD) is a
life threatening complication of SCT with poor prognosis due to
infection related mortality. We investigated the combined use of
Dacluzimab, a humanised monoclonal antibody (Mab) targeting
IL-2 and Inﬂiximab, a chimeric human/mouse anti-TNF a, in
order to selectively delete alloreactive cells and target 2 different
points in the cytokine cascade responsible for aGvHD.
Fifteen consecutive children (median age 4.5 years) with SRGvHD
(deﬁned as aGvHD that failed to improve after 1 week of at least
2mg/kg/day ofMethylprednisolone) were treated. Donors wereMSD
or MFD (n3), MUD (n9) and mismatched UD (n3). All 15
patients had involvement of the skin, 14 of the lower gut and 5 of the
liver. All patients had grade 3 (n5) or 4 (n10) GVHD. Patients
were treated with a combination of Daclizumab (1mg/kg, days
1,4,8,15,22) and Inﬂiximab (10mg/kg, days 1,8,15,22), with rapid
reduction of steroid dosage to 1mg/kg. Median time of starting the
Mabs was day 17 from the onset of GvHD. All children received
anti-fungal prophylaxis and prospective viral monitoring.
12/15 patients responded (7 CR, 5 PR), with a median response
time of 13 days. Two patients developed recurrent GvHD and
received a second course of Mabs. There were 10 episodes of viral
reactivations (CMV 4, adeno 3, EBV 3) and 3 patients developed
probable fungal infections. Impressively, however, there were no
infection related deaths. T-cell responses to CMV after mAb
infusion were assessed in 5 patients using the IFN-g ELISPOT
assay. As shown in the table below, 4 patients showed a signiﬁcant
response to CMV (deﬁned as 40 SFC per 2 105 PBMC) in the
ﬁrst 3 months after treatment and at least 1 patient (UPN2) was
able to mount a de novo response to CMV after mAb therapy.
At a median follow-up of 30 months, 10/15 (66%) children are
alive. 3 primary non-responders died of progressive GvHD, as did
1 patient who achieved a PR but subsequently developed bronchi-
olitis obliterans and 1 patient who died of Pseudomonas sepsis.
5/10 evaluable patients developed chronic GVHD (3 limited, 2
extensive), which has resolved in 2 cases. This data suggests that
combination treatment with Daclizumab and Inﬂiximab is a highly
effective therapeutic option for patients with SRGvHD and is
associated with preservation of anti-viral responses and a low in-
fection related mortality compared to standard therapies.
CMV-speciﬁc T-cell responses post- mAbs (IFN-gamma SFC/2 
10e5 PBMC)
Pre-mAbs 1 month 3 months
UPN 1 NE 0 41
UPN 2 0 2 98
UPN 13 81 138 23
UPN 14 NE 73 148
UPN 15 11 NE 0
Normal donor 68
NE not evaluated
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HISTONE DEACETYLASE INHIBITORS INDUCE INDOLEAMINE 2, 3-DI-
OXYGENASE AND MODULATE DENDRITIC CELL FUNCTIONS
Reddy, P.1, Sun, Y.1, Maeda, Y.1, Weisiger, E.1, Duran-Struuck, R.1,
Dinarello, C.2, Ferrara, J.L.1 1University of Michigan Medical Center,
Ann Arbor, MI; 2University of Colorado, Denver, CO.
Recent studies have demonstrated that suberoylanilide hydroxamic
acid (SAHA), a histone deacetylase (HDAC) inhibitor, reduces exper-
imental acute graft-versus-host disease (GVHD). We investigated the
cellular-molecular mechanisms of immuno-modulation by two
HDAC inhibitors, SAHA and ITF 2357. Stimulation of bone marrow
derived dendritic cells (DCs) with various TLR ligands (lipopolysac-
charide (LPS), PGN, CpG) after pretreatment with either SAHA
caused a signiﬁcant reduction in the secretion of TNF-, IL-12p70
and IL-6 compared to the untreated controls (P 0.01). Similar
effects were seen using human peripheral blood mononuclear cell
derived DCs. Pre-treatment of DCs also signiﬁcantly reduced their in
vitro and in vivo stimulation of allogeneic T cells as measured by
proliferation and IFN- production (P0.05), which was not reversed
by anti-IL-10 or anti-TGF. No signiﬁcant difference was observed
in the viability of pretreated and control DCs. Pretreatment signiﬁ-
cantly suppressed the expression of CD40 and CD80. When mixed
with normal DCs at 1:1 ratio, SAHA treated DCs suppressed alloge-
neic T cell responses in a contact dependent manner. When DCs
from B6 MHC Class II deﬁcient (H-2b) were treated with SAHA and
co-cultured with wild type B6 DCs along with puriﬁed allogeneic
BALB/c (H-2d) CD4 T cells in an MLR, the allo-CD4 T cells
proliferated demonstrating the regulation to be dependent on contact
between SAHA treated DCs and T cells. To determine the molecular
mechanism, we analyzed for the expression of indoleamine 2, 3-di-
oxygenase (IDO) and found that both SAHA and ITF 2357 increased
IDO at the mRNA and protein levels. A functional role for IDO was
conﬁrmed by the blockade of its induction with speciﬁc small inter-
fering RNA (siRNA) in SAHA mediated suppression if TNF- . To
address the in vivo relevance of this suppression, we utilized the
[BALB/c3B6] model of acute GVHD. B6 animals received 11Gy on
day -1 and injected with of 5 million B6 SAHA treated or control DCs
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